세계의 차세대 항체 의약품 시장 보고서(2025년)

Next Generation Antibody Drug Global Market Report 2025

US $ 4,490 ￦ 6,233,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,010,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,786,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

차세대 항체 의약품 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 15.8%의 연평균 성장률로 297억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 맞춤형 의료에 대한 수요 증가, 의약품 파이프라인의 확대, 의료에 대한 인식 증가, 연구 협력 증가, 고령화 인구 증가 등이 될 것으로 예상됩니다. 예측 기간의 주요 동향으로는 항체약물접합체의 발전, 이중특이성항체의 기술 발전, 차세대 시퀀서 통합, 단백질 공학의 발전, 유전자 치료 통합의 발전 등을 꼽을 수 있습니다.

맞춤의료가 강조되면서 차세대 항체 의약품 시장의 확대가 예상됩니다. 맞춤의료는 환자의 유전적, 환경적, 생활습관적 요인을 고려하여 보다 효과적이고 타겟화된 치료를 제공하기 위해 의료 및 치료 접근법을 환자 개개인에게 맞추는 것입니다. 이러한 맞춤형 의료로의 전환은 보다 정확한 진단과 맞춤형 치료 계획을 가능하게 하는 유전체 염기서열 분석의 발전에 힘입어 더욱 가속화되고 있습니다. 차세대 항체 의약품은 환자 고유의 유전적 체질과 질병 특성에 맞는 치료법을 개발할 수 있게함으로써 효능을 높이고 부작용을 줄임으로써 이러한 추세를 뒷받침하고 있습니다. 예를 들어, 2024년 2월 맞춤형 의료를 추진하는 미국 기반 단체인 맞춤형 의료연합(Personalized Medicine Coalition)은 2023년 미국 식품의약국(FDA)이 희귀질환에 대한 16개의 새로운 맞춤형 치료제를 승인했으며, 이는 2022년 6개에서 증가했다고 보고했습니다. 이처럼 맞춤형 의료에 대한 관심이 높아지면서 차세대 항체 의약품 시장을 주도하고 있습니다.

차세대 항체 의약품 시장의 기업들은 표적 암 치료를 개선하고, 치료 효과를 높이고, 전신 독성을 최소화하기 위해 항체약물접합체(ADC)와 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 종양세포를 특이적으로 타겟팅할 수 있도록 합니다. 예를 들어, 2024년 1월 독일 바이오테크 기업 BioNTech SE는 중국 제약사 Duality Biologics(Suzhou) Co.에 대해 미국 FDA로부터 패스트트랙 지정을 받았습니다. 이 약물전달은 듀얼리티 바이오의 DITAC(Duality Immune Toxin Antibody Conjugates) 플랫폼을 이용한 것으로, 고활성 세포독성 페이로드와 단클론항체를 결합하여 암세포에 정확한 전달을 보장합니다. BNT325/DB-1305는 건강한 조직에 대한 피해를 최소화하면서 암세포를 선택적으로 표적화할 수 있어 치료 효과를 높이고 부작용을 줄이는 데 중요한 이점이 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 차세대 항체 의약품 시장 : PESTEL 분석(정치·사회·기술·환경·법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 차세대 항체 의약품 시장 : 성장률 분석
• 세계의 차세대 항체 의약품 시장 규모·성장률 : 실적치, 2019-2024년
• 세계의 차세대 항체 의약품 시장 규모·성장률 : 예측치, 2024-2029년, 2034년
• 세계의 차세대 항체 의약품 시장 : 총유효과 시장(TAM)

제6장 시장 세분화

• 세계의 차세대 항체 의약품 시장 : 제품 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 단클론항체
• 이중특이성항체
• 항체약물접합체
• 기타 종류
• 세계의 차세대 항체 의약품 시장 : 작용기전별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 체크포인트 억제제
• 면역조절제
• 수용체 차단제
• 표적 세포 상해제
• 중화 항체
• 세계의 차세대 항체 의약품 시장 : 전달 방법별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 정맥내(IV) 투여
• 피하 투여
• 근육내 투여
• 경구 제제
• 경피 전달 시스템
• 세계의 차세대 항체 의약품 시장 : 용도별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 종양
• 자가면역질환
• 감염증
• 기타 용도
• 세계의 차세대 항체 의약품 시장 : 최종사용자별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 병원
• 연구기관
• 전문 클리닉
• 기타 최종사용자
• 세계의 차세대 항체 의약품 시장(단클론항체) : 제품 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 인간 단클론항체
• 마우스 단클론항체
• 인간화 단클론항체
• 키메라 단클론항체
• 세계의 차세대 항체 의약품 시장(이중특이성항체) : 제품 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 체크포인트 억제제 기반 이중특이성항체
• 사이토카인 조절용 이중특이성항체
• 반감기 연장 기술을 이용한 이중특이성항체
• T세포 인게이저
• 세계의 차세대 항체 의약품 시장(항체약물접합체) : 제품 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 절단성 링커 항체약물접합체
• 비절단성 링커 항체약물접합체
• 부위 특이적 결합 항체약물접합체
• 세계의 차세대 항체 의약품 시장(기타 종류) : 제품 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• Teclistamab
• Mosunetuzumab

제7장 지역별·국가별 분석

• 세계의 차세대 항체 의약품 시장 : 지역별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 세계의 차세대 항체 의약품 시장 : 국가별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 차세대 항체 의약품 시장 : 경쟁 구도
• 차세대 항체 의약품 시장 : 기업 개요
  • Actinium Pharmaceuticals Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
  • Pfizer Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
  • F. Hoffmann-La Roche Ltd.(개요, 제품 및 서비스, 전략, 재무 분석)
  • Bristol-Myers Squibb Company(개요, 제품 및 서비스, 전략, 재무 분석)
  • AstraZeneca plc(개요, 제품 및 서비스, 전략, 재무 분석)

제31장 기타 주요 기업과 혁신적 기업

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Kyowa Hakko Kirin Co. Ltd.
• Samsung Biologics Co. Ltd.
• WuXi Biologics Inc.
• Akeso Inc.
• Xencor Inc.
• ImmunoGen Inc.
• Philogen S.p.A.
• Telix Pharmaceuticals Limited

제32장 세계 시장 : 경쟁 벤치마킹·대시보드

제33장 주요 기업 인수합병(M&A)

제34장 최근의 시장 동향

제35장 시장 잠재력 높은 나라·부문과 전략

• 차세대 항체 의약품 시장 : 최신 기회를 제공하는 국가(2029년)
• 차세대 항체 의약품 시장 : 최신 기회를 제공하는 부문(2029년)
• 차세대 항체 의약품 시장 : 성장 전략(2029년)
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Next-generation antibody drugs are advanced therapeutic antibodies developed to target specific antigens with greater precision and efficacy, often incorporating innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to enhance disease treatment outcomes by improving targeting abilities and reducing side effects.

The main product types of next-generation antibody drugs include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are identical copies of a single antibody, created by cloning a unique immune cell, and are used to treat various conditions such as cancer and autoimmune disorders. Their mechanisms of action include checkpoint inhibitors, immune modulators, receptor blockers, targeted cytotoxic agents, and neutralizing antibodies. Delivery methods for these drugs include intravenous (IV), subcutaneous, intramuscular administration, oral formulations, and transdermal delivery systems. They are applied in oncology, autoimmune diseases, infectious diseases, and other areas, and are used by hospitals, research institutes, specialty clinics, and other healthcare providers.

The next generation antibody drug market research report is one of a series of new reports from The Business Research Company that provides next generation antibody drug market statistics, including the next generation antibody drug industry's global market size, regional shares, competitors with the next generation antibody drug market share, detailed next-generation antibody drug market segments, market trends and opportunities, and any further data you may need to thrive in the next generation antibody drug market. This next generation antibody drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation antibody drug market size has grown rapidly in recent years. It will grow from $14.26 billion in 2024 to $16.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth during the historic period can be attributed to the increasing demand for targeted therapies, rising cancer prevalence, growing adoption of immuno-oncology therapies, heightened focus on autoimmune diseases, and expanding regulatory support.

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $29.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period is expected to be driven by rising demand for personalized medicine, expanding drug pipelines, increasing healthcare awareness, more research collaborations, and a growing aging population. Major trends in the forecast period include advancements in antibody-drug conjugates, technological progress in bispecific antibodies, integration of next-generation sequencing, developments in protein engineering, and advancements in gene therapy integration.

The growing emphasis on personalized medicine is anticipated to drive the expansion of the next-generation antibody-drug market. Personalized medicine tailors healthcare and treatment approaches to individual patients, considering their genetic, environmental, and lifestyle factors to provide more effective and targeted therapies. This shift toward personalized medicine is fueled by advancements in genomic sequencing, which allow for more accurate diagnoses and customized treatment plans. Next-generation antibody drugs support this trend by enabling the development of therapies tailored to a patient's unique genetic makeup and disease characteristics, enhancing efficacy and reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization promoting personalized medicine, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Thus, the growing emphasis on personalized medicine is driving the next-generation antibody drug market.

Companies in the next-generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates (ADCs), to improve targeted cancer therapies, enhance treatment efficacy, and minimize systemic toxicity. ADCs combine a monoclonal antibody with a cytotoxic drug via a linker, allowing the drug to specifically target tumor cells while sparing healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology firm, partnered with Duality Biologics (Suzhou) Co. Ltd., a Chinese pharmaceutical company, to receive a Fast Track designation from the U.S. FDA for their ADC candidate, BNT325/DB-1305, intended to treat platinum-resistant ovarian cancer. This drug utilizes DualityBio's DITAC (Duality Immune Toxin Antibody Conjugates) platform, which pairs a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery to cancer cells. The ability of BNT325/DB-1305 to selectively target cancer cells while minimizing harm to healthy tissue is a key advantage in enhancing treatment outcomes and reducing side effects.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed sum. Through this acquisition, Johnson & Johnson aims to enhance its oncology portfolio by developing advanced, targeted antibody-drug conjugates that improve outcomes and minimize side effects for patients with hard-to-treat cancers. Ambrx Biopharma is dedicated to advancing the development of next-generation antibody-drug conjugates.

Major players in the next generation antibody drug market are Actinium Pharmaceuticals Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited.

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in next generation antibody drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation antibody drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Antibody Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation antibody drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation antibody drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation antibody drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Other Types
• 2) By Mechanism Of Action: Checkpoint Inhibitors; Immune Modulators; Receptor Blockers; Targeted Cytotoxic Agents; Neutralizing Antibodies
• 3) By Delivery Method: Intravenous (IV) Administration; Subcutaneous Administration; Intramuscular Administration; Oral Formulations; Transdermal Delivery Systems
• 4) By Application: Oncology; Autoimmune Diseases; Infectious Diseases; Other Applications
• 5) By End User: Hospitals; Research Institutes; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Human Monoclonal Antibodies; Murine Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies
• 2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics; Bispecific Antibodies For Cytokine Modulation; Bispecific Antibodies With Extended Half-Life Technologies
• 3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates; Non-Cleavable Linker Antibody-Drug Conjugates; Site-Specific Conjugated Antibody-Drug Conjugates
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Antibody Drug Market Characteristics

3. Next Generation Antibody Drug Market Trends And Strategies

4. Next Generation Antibody Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Next Generation Antibody Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next Generation Antibody Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next Generation Antibody Drug Market Growth Rate Analysis
• 5.4. Global Next Generation Antibody Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next Generation Antibody Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next Generation Antibody Drug Total Addressable Market (TAM)

6. Next Generation Antibody Drug Market Segmentation

• 6.1. Global Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Bispecific Antibodies
• Antibody-Drug Conjugates
• Other Types
• 6.2. Global Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Immune Modulators
• Receptor Blockers
• Targeted Cytotoxic Agents
• Neutralizing Antibodies
• 6.3. Global Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Administration
• Subcutaneous Administration
• Intramuscular Administration
• Oral Formulations
• Transdermal Delivery Systems
• 6.4. Global Next Generation Antibody Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Other Applications
• 6.5. Global Next Generation Antibody Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Specialty Clinics
• Other End Users
• 6.6. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Monoclonal Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Monoclonal Antibodies
• Murine Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• 6.7. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Bispecific Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitor-Based Bispecifics
• Bispecific Antibodies For Cytokine Modulation
• Bispecific Antibodies With Extended Half-Life Technologies
• T-Cell Engagers
• 6.8. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linker Antibody-Drug Conjugates
• Non-Cleavable Linker Antibody-Drug Conjugates
• Site-Specific Conjugated Antibody-Drug Conjugates
• 6.9. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teclistamab
• Mosunetuzumab

7. Next Generation Antibody Drug Market Regional And Country Analysis

• 7.1. Global Next Generation Antibody Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next Generation Antibody Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Antibody Drug Market

• 8.1. Asia-Pacific Next Generation Antibody Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Antibody Drug Market

• 9.1. China Next Generation Antibody Drug Market Overview
• 9.2. China Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Antibody Drug Market

• 10.1. India Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Antibody Drug Market

• 11.1. Japan Next Generation Antibody Drug Market Overview
• 11.2. Japan Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Antibody Drug Market

• 12.1. Australia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Antibody Drug Market

• 13.1. Indonesia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Antibody Drug Market

• 14.1. South Korea Next Generation Antibody Drug Market Overview
• 14.2. South Korea Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Antibody Drug Market

• 15.1. Western Europe Next Generation Antibody Drug Market Overview
• 15.2. Western Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Antibody Drug Market

• 16.1. UK Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Antibody Drug Market

• 17.1. Germany Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Antibody Drug Market

• 18.1. France Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Antibody Drug Market

• 19.1. Italy Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Antibody Drug Market

• 20.1. Spain Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Antibody Drug Market

• 21.1. Eastern Europe Next Generation Antibody Drug Market Overview
• 21.2. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Antibody Drug Market

• 22.1. Russia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Antibody Drug Market

• 23.1. North America Next Generation Antibody Drug Market Overview
• 23.2. North America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Antibody Drug Market

• 24.1. USA Next Generation Antibody Drug Market Overview
• 24.2. USA Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Antibody Drug Market

• 25.1. Canada Next Generation Antibody Drug Market Overview
• 25.2. Canada Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Antibody Drug Market

• 26.1. South America Next Generation Antibody Drug Market Overview
• 26.2. South America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Antibody Drug Market

• 27.1. Brazil Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Antibody Drug Market

• 28.1. Middle East Next Generation Antibody Drug Market Overview
• 28.2. Middle East Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Antibody Drug Market

• 29.1. Africa Next Generation Antibody Drug Market Overview
• 29.2. Africa Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Antibody Drug Market Competitive Landscape And Company Profiles

• 30.1. Next Generation Antibody Drug Market Competitive Landscape
• 30.2. Next Generation Antibody Drug Market Company Profiles
  • 30.2.1. Actinium Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Antibody Drug Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Biogen Inc.
• 31.8. Kyowa Hakko Kirin Co. Ltd.
• 31.9. Samsung Biologics Co. Ltd.
• 31.10. WuXi Biologics Inc.
• 31.11. Akeso Inc.
• 31.12. Xencor Inc.
• 31.13. ImmunoGen Inc.
• 31.14. Philogen S.p.A.
• 31.15. Telix Pharmaceuticals Limited

32. Global Next Generation Antibody Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Antibody Drug Market

34. Recent Developments In The Next Generation Antibody Drug Market

35. Next Generation Antibody Drug Market High Potential Countries, Segments and Strategies

• 35.1 Next Generation Antibody Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next Generation Antibody Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next Generation Antibody Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료